Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
  • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/10—Antimycotics
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
  • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
  • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

• the present invention relates to a crystal of luliconazole and a pharmaceutical preparation containing the crystal.
• Luliconazole is an antifungal agent which has the structure shown below and which is excellent in the action on fungi.
• luliconazole is widely used as a pharmaceutical or medicine for tinea pedis and tinea corporis, and it is going to be applied for the action on tinea unguium.
• the pharmaceutical or medicine for tinea pedis and tinea corporis, and it is going to be applied for the action on tinea unguium.
• luliconazole has low water solubility.
• luliconazole is solubilized in the component of the pharmaceutical preparation, it is necessary to perform the heating step. It has been demanded to develop any means for improving the solubility of luliconazole and shorten the heating time in the heating step.
• the shortening or reduction of the heating step has such merits that the generation or
• any isomer generated or formed in this step is not only suppressed but the long-term stability can be also secured by lowering the initial value of the isomer amount. In other words, it is affirmed that the shortening or reduction of the dissolving step results in the great improvement in the quality.
• Patent Documents
• Patent Document 1 WO2007/102241;
• Patent Document 2 WO2007/102242;
• Patent Document 3 WO2007/102243;
• Patent Document 4 WO2009/031642 ;
• Patent Document 5 WO2009/031643;
• Patent Document 6 WO2009/031644 ;
• Patent Document 7 JP9-100279A.
• the present invention has been made in the circumstances as described above, an object of which is to provide means for improving the solubility of luliconazole in order to improve the stability of a pharmaceutical preparation .
• the present inventors have repeatedly performed diligent researches and efforts in order to seek for any means for improving the solubility of luliconazole so that the stability of a pharmaceutical preparation is improved.
• a crystal containing short chain alcohol and a composition for an active pharmaceutical ingredient have such a characteristic, and thus the invention has been completed. That is, the present invention resides in the gist or essential characteristics shown .below.
• ⁇ 2> The crystal as defined in ⁇ 1>, wherein a content of the short chain alcohol is 100 to 10,000 ppm with respect to a total amount of the crystal.
• ⁇ 4> The crystal as defined in any One of ⁇ 1> to ⁇ 3>, wherein the crystal is produced by recrystallizing with the short chain alcohol which may contain water, followed by being dried, and added with the short chain alcohol if necessary.
• composition for an active pharmaceutical ingredient containing the crystal as defined in any one of ⁇ 1> to ⁇ 4>.
• ⁇ 6> A pharmaceutical preparation obtained by blending the composition for the active pharmaceutical ingredient as defined in ⁇ 5>.
• preparation comprising a step of dissolving, in a solvent, the crystal as defined in any one of ⁇ 1> to ⁇ 4> or the composition for the active pharmaceutical ingredient as defined in- ⁇ 5> .
• ⁇ 8> A pharmaceutical preparation produced by the method as defined in ⁇ 7>.
• Fig. 1 shows results of a solubility test for crystals of Examples and a crystal of Comparative Example.
• the crystal of the present invention is characterized in that the crystal contains luliconazole and the short chain alcohol.
• the crystal of the present invention can be also referred to as a crystal composite (complex) containing luliconazole and the short chain alcohol, or a crystal matrix containing luliconazole and the short chain alcohol.
• crystal composite complex
• crystal matrix containing luliconazole and the short chain alcohol.
• the short chain alcohol described above can be any short chain alcohol.
• alcohol having a straight chain or a side chain and having a number of carbon atom or atoms of 1 to 4 such as methanol, ethanol, isopropyl alcohol, and butanol [for example, methanol, ethanol, 1-propanol (propyl alcohol), 2-propanol (isopropyl alcohol) , 1-butanol (n-butyl alcohol) , 2-butanol (sec-butyl alcohol), 2-methyl-l-propanol (isobutyl alcohol), and 2- methyl-2-prppanol (tert-butyl alcohol) ] .
• ethanol ethanol, 1-propanol (propyl alcohol), 2-propanol (isopropyl alcohol)
• 1-butanol (n-butyl alcohol) 2-butanol (sec-butyl alcohol)
• 2-methyl-l-propanol (isobutyl alcohol) 2- methyl-2-prppanol (tert-butyl alcohol)
• the crystal may contain two or more alcohols selected from the alcohols as described above.
• the content of alcohol having the short chain as described above is preferably 100 to 10,000 ppm and more preferably 500 to 5,000 ppm with respect to the total mass of the crystal, for the following reason. That is, if the content is too small, the effect to improve the solubility is not provided in some cases. If the content is too large, the stability of the whole crystal is deteriorated in some cases.
• the content of luliconazole is preferably not less than 95% by mass and more preferably not less than 99% by mass with respect to the total mass of the crystal.
• the crystal as described above can be produced by, for example, by recrystallizing luliconazole with the short chain alcohol which may contain water, collecting crystals by filtration, drying the crystals while
• the short chain alcohol performing blowing, and allowing the short chain alcohol to be contained as desired, by measuring the amount of the short chain alcohol and adding the short chain alcohol if the amount of the short chain alcohol is not within a preferred range. On the other hand, if the amount of the short chain alcohol is too large, the adjustment can be also performed by further performing drying while
• the recrystallization may be performed by using water- containing alcohol, or water may be used as a poor solvent.
• the poor solvent method is such a method that water, which is in an amount sufficient to cause deposition, is added to an alcohol solution containing luliconazole .
• the recrystallization is performed with alcohol containing 10% water, which is preferred in view of the purity to be finally obtained.
• the recrystallization can be performed in accordance with any ordinary recrystallization method.
• the alcohol as described above may be used together with water upon the use.
• the alcohol as described above may be used in a state in which water is previously contained.
• the amount of usable water is preferably exemplified, for example, by 9 to 80%, 30 to 80%, 50 to 75%, or about 70% at the maximum with respect to the total amount of the alcohol which may contain water.
• composition for active pharmaceutical ingredient of the present invention is a composition for active pharmaceutical ingredient of the present invention.
• composition for the active pharmaceutical is the composition for the active pharmaceutical
• ingredient of the present invention can contain substances, impurities, and isomers within a range permitted as the active pharmaceutical ingredient, other than luliconazole and the short chain alcohol.
• the composition consists essentially of luliconazole and the short chain alcohol.
• the crystal of the present invention and the composition for the active pharmaceutical ingredient obtained as described above have the excellent solubility with respect to the solvent. Therefore, the crystal of the present invention and the composition for the active pharmaceutical ingredient have the function to suppress, for example, the production of any isomer in the production of the pharmaceutical preparation to be produced by
• the crystal of the present invention and the composition for the active pharmaceutical ingredient can be used as the raw material for producing the
• the crystal of the present invention or the composition for the active pharmaceutical ingredient described above is contained.
• the pharmaceutical preparation in which the content of luliconazole exceeds 5% by mass, requires a considerable period of time to perform the dissolving step. Therefore, the pharmaceutical preparation of the present invention is preferred in view o-f the shortening or
• luliconazole is 0.1 to 30% by mass with respect to the total amount of the pharmaceutical preparation. More preferably, the content of luliconazole is 0.5 to 15% by mass.
• an oral administration agent such as a tablet or the like, the rate of dissolution is excellent, which is preferred.
• the oral administration pharmaceutical preparation as described above also belongs to the
• the time required for the dissolving step depends on, for example, the processing condition (treatment condition) and the content of luliconazole in the pharmaceutical preparation as well. However, the time required for the dissolving step, which is required when the crystal of the present invention or the composition for the active
• pharmaceutical ingredient is used in the dissolving step to prepare, for example, a pharmaceutical preparation in which the content of luliconazole is 0.1 to 30% by mass with respect to the total amount of the pharmaceutical
• preparation may be not more than 80%, preferably not more than 75%, and more preferably not more than 70% as compared with the time which is required for the dissolving step when any conventionally available luliconazole is used.
• invention can be produced by performing the process or treatment in accordance with any ordinary method while appropriately adding thereto, for example, solvent,
• coloring agent antioxidant, chelating agent,
• disintegrating agent excipient, binding agent, coating agent, and taste/odor-correcting agent other than the crystal of the present invention or the composition for the active pharmaceutical ingredient.
• the amounts of isomers are suppressed in relation to the initial values obtained immediately after the production of luliconazole .
• the amounts of isomers (SE isomer, Z isomer) , which are obtained in relation to the initial values provided immediately after the production of luliconazole, may be as follows as compared with the case in which the crystal having such a crystal habit that the (11-1) plane is the specific growth surface produced by conventional methods such as a method by recrystallizing from n-hexane-ethyl acetate is used.
• the amount of isomer may be not more than 80%, preferably not more than 70%, and more preferably not more than 60%.
• the amount of isomer may be not more than 70%, preferably not more than 60%, and more preferably not more than 50%.
• the sum may be not- more than 80%, preferably not more than 70%, and more preferably not more than 60%.
• the crystal of the present invention or the composition for the active pharmaceutical ingredient is especially preferred as the active ingredient for the pharmaceutical medicament
• composition of the present invention is preferably used to treat or cure the disease caused by any fungus or prevent the deterioration of the disease by utilizing the characteristic of luliconazole .
• pharmaceutical preparation of the present invention is also preferably used to treat the disease caused by any protozoa such as Trichomonas vaginalis or prevent the deterioration of the disease.
• the disease caused by any fungus can be exemplified by tinea pedis such as athlete's foot, tinea corporis such as candidiasis and tinea versicolor, and trichophytosis of hard keratin portion such as tinea unguium. It is especially preferable to use the
• composition of the present invention for treating the disease of the hard keratin portion such as tinea unguium, because the effect thereof is remarkable.
• the effect of the pharmaceutical composition of the present invention is expressed on the nail especially preferably. However, the effect is also exerted on any ordinary dermatomycosis .
• dermatomycosis as described above can be exemplified, for example, by the tinea pedis and the trichophytosis of the propagation in horny substance type, the trichophytosis of the propagation in horny substance type appearing, for example, in the heel and being included in the tinea pedis.
• the dermatomycosis described above it is preferable to make the application to the trichophytosis of the propagation in horny substance type on which any ordinary agent or drug hardly exerts the effect, because the effect of the present invention remarkably arises.
• the mode of use can be appropriately selected while considering, for example, the body weight, the age, the sexuality, and the symptoms or condition of the
• luliconazole preferable to administer luliconazole in an amount of 0.01. to 1 g per day in ordinary cases. Reference can be made to the amount of use of luliconazole ordinarily used for the disease caused by any fungus.
• the application in an appropriate amount to the disease portion once or several times a day. It is preferable that the treatment as described above is performed every day.
• the tinea unguium luliconazole as the active ingredient, which, is in an amount that cannot be brought about by any ordinary pharmaceutical preparation, can be transferred into the nail. Accordingly, the tinea unguium can be cured by means of only the external
• the pharmaceutical composition of the present invention is administered without taking any antifungal agent for a long period of time. Further, the recurrence and the reinfection cause great problems in relation to the tinea unguium. However, it is possible to avoid the recurrence and the reinfection as described above by administering the pharmaceutical composition of the present invention for 1 week to 2 weeks after the quietness of symptoms. In such a mode, the pharmaceutical composition of the present
• the single crystal X-ray structure analysis was performed for Crystal 1 of the present invention (name of machine type of apparatus: RU-H2R, name of manufacturer: Rigaku Corporation, Condition: X-ray source: CuKa, measurement temperature: 26°C, tube voltage: 50 kV, tube current: 180 mA, 29max: 150.0°, structure analysis method: direct method (SHELX 86) ) .
• the crystal system, the space group, the lattice constant, and the R factor, which were obtained from measured values, were as follows.
• Crystals 2, 3 The alcohol contents of crystals (Crystals 2, 3) obtained by changing the recrystallization condition of Example 1 were measured, and the state of dissolution in ethanol was also observed with naked eyes. Results are shown in Table 2. Crystal 2 and Crystal 3 are the crystals of the present invention, wherein the dissolution state was satisfactory as well. That is, it is understood that the solubility is especially improved when ethanol is contained by not less than 1,000 ppm.
• a pharmaceutical preparation (lotion preparation) was manufactured by using Crystal 1 of the present invention. That is, formulation components were heated, stirred, and solubilized. After confirming the solubilization,
• the alcohol content of Crystal 4 obtained by changing the recrystallization condition of Example 1 was measured, and the state of dissolution in ethanol was also compared with those of Crystal of Comparative Example of Example 1 and Crystal 3 to compare the solubility.
• Crystal 4 was prepared as follows. That is, 150 mL of ethanol was added to 5 g of luliconazole, followed by being refluxed and solubilized. Cooling was performed slowly until arrival at 70°C while stirring, and this temperature was retained for 20 minutes. After that, 20 mL of water was added thereto, followed by being stirred and cooled. Deposited crystals were collected by filtration, followed by being dried for 48 hours while performing blowing at 30°C to obtain Crystal 4 of the present invention. This sample had an ethanol content of 262 ppm. As for the solubility, there is given Comparative Example « Crystal 4 ⁇ Crystal 3. It is understood that the effect of the present invention is provided in the case of Crystal 4. Accordingly, it is speculated that the lower limit value permitted for alcohol is 100 ppm.
• the alcohol content of Crystal 5 obtained by changing the recrystallization condition of Example 1 was measured, and the state of dissolution in ethanol was also compared with those of Crystal of Comparative Example of Example 1 and Crystal 2 to compare the solubility.
• Crystal 5 was prepared as follows. That is, 150 mL of ethanol was added to 5 g of luliconazole , followed by being refluxed and solubilized. Cooling was performed slowly until arrival at 80°C while stirring, and this temperature was retained for 5 minutes. 15 mL of water was gradually added thereto, followed by being stirred and cooled.
• Crystal 5 Crystal 5 of the present invention.
• This crystal had an ethanol content of 7029 ppm.
• the alcohol content of Crystal 6 obtained by changing the recrystallization condition of Example 1 was measured, and the state of dissolution in ethanol was also compared with those of Crystal of Comparative Example of Example 1, Crystal 4, and Crystal 3 to compare the solubility.
• the alcohol content of Crystal 7 obtained by changing the recrystallization condition of Example 1 was measured, and the state of dissolution in ethanol was also compared with those of Crystal of Comparative Example of Example 1 and Crystal 5 to compare the solubility.
• Crystal 7 was prepared as follows. That is, 200 mL of aqueous solution of 90% ethanol was added to 5 g of
• Crystal 7 had an ethanol content of 4146 ppm.
• any one of the crystals of the present invention is more excellent in solubility than the crystal of Comparative Example.
• the alcohol content (content of alcohol used in recrystallization) of compositions obtained by changing the recrystallization condition of Example 1 was measured, and the state of dissolution in ethanol was also observed with naked eyes. The results are shown in Table 4.
• Crystal 8 was recrystallized by procedures as
• Crystal 9 was obtained by the same procedures as described above except that 50 mL of methanol was added to 10 g of luliconazole, and 150 mL of water was added thereto. Crystal 10 was obtained by the same
• Crystal 11 was obtained by the same procedures as described above except that 200 mL of 2- propanol was added to 10 g of luliconazole, and no water was added thereto. All of the crystals are the crystals of the present invention, wherein the dissolution state was satisfactory as well. That is, it is understood that the solubility is especially improved when the alcohol having a number of carbon atom or atoms of 1 to 4 is contained by not less than 500 ppm, more preferably not less than 1,000 ppm.
• Crystal which was obtained by performing recrystallization from a mixture solution of ethyl acetate and n-hexane and which contained no alcohol, was used as a comparative example (comparative crystal) .
• Direct effects of luliconazole were investigated by utilizing Trichomonas vaginalis (clinically isolated strain). Samples such that 5.08 mg of comparative crystal was added in "Trichomonas medium F" (Fuji Pharma) , 5.08 mg of crystal 10 was added in the medium, and 5 ⁇ of water was added in the medium (control) were prepared. 200 mL of culture solution containing 3.93 x 10 5 cells/mL of
• Trichomonas vaginalis was added to each of the samples, followed by being cultured for 4 days at 37 °C . After that, cells of Trichomonas were counted on a hemocytometer . The results are shown in Table 5. Between these three samples, significant difference was confirmed at a critical value of not more than 1%. From this result, it is
• crystal of the present invention has excellent antiprotozoal effect.
• tablet was prepared, and its hardness was measured.
• PTB311 Pulharma Test GmbH
• Condition of tableting was performed at tableting pressure of 1 ton/cm 2 by
• Comparative example was prepared by performing same procedures as described above by using comparative crystal. Averages of 6 tablets of each sample were shown in Table 7. From this result, it is understood that crystal of the present invention has high hardness and has excellent physical stability. Accordingly, it is assumed that a tablet having high hardness can be obtained by utilizing the active ingredient containing alcohol since the active ingredient containing alcohol has strong affinity between the active ingredients .
• the present invention can be applied to pharmaceuticals .

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Dermatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (7)

Applications Claiming Priority (4)

Publications (1)

Family

ID=49237577

Family Applications (1)

Country Status (7)

Cited By (1)

Families Citing this family (13)

Citations (9)

Family Cites Families (13)

• 2013
  • 2013-09-06 IN IN2929DEN2015 patent/IN2015DN02929A/en unknown
  • 2013-09-06 JP JP2013185320A patent/JP5589130B1/ja active Active
  • 2013-09-06 RU RU2015113638A patent/RU2622644C2/ru active
  • 2013-09-06 WO PCT/JP2013/074775 patent/WO2014042231A1/en active Application Filing
  • 2013-09-06 CN CN201380018386.2A patent/CN104284662A/zh active Pending
  • 2013-09-06 US US14/019,997 patent/US9012484B2/en active Active
  • 2013-09-06 EP EP13766723.4A patent/EP2895165B1/en active Active

Patent Citations (13)

Also Published As

Similar Documents

Legal Events